Roflumilast Tablet
NDC Package 42571-259-30
Package Information
Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.Limitations of UseRoflumilast tablet is not a bronchodilator and is not indicated for the relief of acute bronchospasm.Roflumilast tablet 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose. This formulation utilizes a tablet delivery system. Marketed by Micro Labs Limited, this product is identified by NDC 42571-259 and is authorized under FDA application ANDA208180.
Identification & Billing
- RxCUI: 1091839 - roflumilast 500 MCG Oral Tablet
- RxCUI: 1091839 - roflumilast 0.5 MG Oral Tablet
- RxCUI: 2001319 - roflumilast 250 MCG Oral Tablet
- RxCUI: 2001319 - roflumilast 0.25 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 42571 - Micro Labs Limited
- 42571-259 - Roflumilast
- 42571-259-30 - 30 TABLET in 1 BOTTLE
- 42571-259 - Roflumilast
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (42571-259). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 42571-259-30 identifies a specific commercial package of 30 tablet in 1 bottle of Roflumilast, a human prescription drug labeled by Micro Labs Limited. This tablet is formulated for oral use and contains roflumilast as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Micro Labs Limited on October 19, 2022. The current certification is valid through December 31, 2027.
How is this Micro Labs Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 42571025930. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.